CY1111384T1 - Διαμορφωση των επιπεδων εκφρασης toy trpv - Google Patents
Διαμορφωση των επιπεδων εκφρασης toy trpvInfo
- Publication number
- CY1111384T1 CY1111384T1 CY20111100350T CY111100350T CY1111384T1 CY 1111384 T1 CY1111384 T1 CY 1111384T1 CY 20111100350 T CY20111100350 T CY 20111100350T CY 111100350 T CY111100350 T CY 111100350T CY 1111384 T1 CY1111384 T1 CY 1111384T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trpv
- toy
- configuration
- expression levels
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of El Displays (AREA)
- Transmitters (AREA)
- Amplitude Modulation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Details Of Television Scanning (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0521351.7A GB0521351D0 (en) | 2005-10-20 | 2005-10-20 | Modulation of TRPV expression levels |
| EP06794999A EP1937281B1 (en) | 2005-10-20 | 2006-10-20 | Modulation of trpv expression levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111384T1 true CY1111384T1 (el) | 2015-08-05 |
Family
ID=35458356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100350T CY1111384T1 (el) | 2005-10-20 | 2011-04-05 | Διαμορφωση των επιπεδων εκφρασης toy trpv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8354385B2 (https=) |
| EP (1) | EP1937281B1 (https=) |
| JP (2) | JP5677721B2 (https=) |
| AT (1) | ATE493994T1 (https=) |
| AU (1) | AU2006305657B2 (https=) |
| CA (1) | CA2626181C (https=) |
| CY (1) | CY1111384T1 (https=) |
| DE (1) | DE602006019458D1 (https=) |
| DK (1) | DK1937281T3 (https=) |
| ES (1) | ES2358538T3 (https=) |
| GB (1) | GB0521351D0 (https=) |
| PL (1) | PL1937281T3 (https=) |
| PT (1) | PT1937281E (https=) |
| SI (1) | SI1937281T1 (https=) |
| WO (1) | WO2007045930A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694091A1 (en) * | 2007-10-01 | 2009-04-09 | Alcon Research, Ltd. | Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2865759B1 (en) * | 2012-06-20 | 2017-05-17 | NapaJen Pharma, Inc. | Nucleic acid complex and nucleic acid-polysaccharide complex |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| KR101681229B1 (ko) | 2013-07-24 | 2016-11-30 | 고려대학교 산학협력단 | TRPV4 활성 억제제로서의 vorinostat의 용도 |
| GB202219829D0 (en) | 2022-12-29 | 2023-02-15 | Ivy Farm Tech Limited | Genetically manipulated cells |
| WO2025215354A1 (en) | 2024-04-08 | 2025-10-16 | Ivy Farm Technologies Limited | Method of culturing an animal cell |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL16768C (https=) | 1924-10-02 | |||
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| EP1495120B1 (en) | 2002-04-18 | 2012-10-10 | Acuity Pharmaceuticals, Inc | Means and methods for the specific modulation of target genes in the eye |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| AU2003254151B2 (en) | 2002-07-24 | 2006-08-31 | Immusol Incorporated | Novel siRNA libraries and their production and use |
| WO2004009796A2 (en) | 2002-07-24 | 2004-01-29 | Immusol Incorporated | Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| CA2881743A1 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| NZ540779A (en) | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
| DE10322662A1 (de) * | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| US7462602B2 (en) | 2003-05-01 | 2008-12-09 | University Of Florida Research Foundation, Inc. | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES |
| MXPA06003949A (es) * | 2003-10-07 | 2006-06-27 | Renovis Inc | Compuestos amida como ligandos del canal de ion y su uso. |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005076998A2 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| CA2584502A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | 2-methylpropanamides and their use as pharmaceuticals |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| HUE033977T2 (en) | 2004-08-23 | 2018-02-28 | Sylentis Sau | Treatment of eye disorders with siRNAs characterized by increased intraocular pressure |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| WO2006099353A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
-
2005
- 2005-10-20 GB GBGB0521351.7A patent/GB0521351D0/en not_active Ceased
-
2006
- 2006-10-20 DE DE602006019458T patent/DE602006019458D1/de active Active
- 2006-10-20 AU AU2006305657A patent/AU2006305657B2/en active Active
- 2006-10-20 DK DK06794999.0T patent/DK1937281T3/da active
- 2006-10-20 WO PCT/GB2006/050342 patent/WO2007045930A2/en not_active Ceased
- 2006-10-20 PL PL06794999T patent/PL1937281T3/pl unknown
- 2006-10-20 SI SI200630965T patent/SI1937281T1/sl unknown
- 2006-10-20 JP JP2008536136A patent/JP5677721B2/ja active Active
- 2006-10-20 ES ES06794999T patent/ES2358538T3/es active Active
- 2006-10-20 CA CA2626181A patent/CA2626181C/en active Active
- 2006-10-20 PT PT06794999T patent/PT1937281E/pt unknown
- 2006-10-20 US US12/090,426 patent/US8354385B2/en active Active
- 2006-10-20 AT AT06794999T patent/ATE493994T1/de active
- 2006-10-20 EP EP06794999A patent/EP1937281B1/en active Active
-
2011
- 2011-04-05 CY CY20111100350T patent/CY1111384T1/el unknown
-
2013
- 2013-01-18 JP JP2013007528A patent/JP2013074902A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1937281B1 (en) | 2011-01-05 |
| DE602006019458D1 (de) | 2011-02-17 |
| AU2006305657B2 (en) | 2011-10-20 |
| ES2358538T3 (es) | 2011-05-11 |
| SI1937281T1 (sl) | 2011-09-30 |
| AU2006305657A1 (en) | 2007-04-26 |
| JP5677721B2 (ja) | 2015-02-25 |
| US8354385B2 (en) | 2013-01-15 |
| ATE493994T1 (de) | 2011-01-15 |
| JP2013074902A (ja) | 2013-04-25 |
| JP2009512673A (ja) | 2009-03-26 |
| PL1937281T3 (pl) | 2011-06-30 |
| PT1937281E (pt) | 2011-03-29 |
| DK1937281T3 (da) | 2011-05-02 |
| CA2626181A1 (en) | 2007-04-26 |
| EP1937281A2 (en) | 2008-07-02 |
| WO2007045930A2 (en) | 2007-04-26 |
| US20100286230A1 (en) | 2010-11-11 |
| HK1120741A1 (en) | 2009-04-09 |
| CA2626181C (en) | 2014-03-18 |
| GB0521351D0 (en) | 2005-11-30 |
| WO2007045930A3 (en) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111384T1 (el) | Διαμορφωση των επιπεδων εκφρασης toy trpv | |
| MX2011013060A (es) | Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| TW200733964A (en) | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions | |
| DE602007008524D1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
| BRPI0520014A2 (pt) | emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco | |
| DE602006009834D1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| JOP20170147A1 (ar) | تركيبات خاصة بالعيون | |
| BRPI0518173A (pt) | composição oftálmica e usos | |
| MX2011013061A (es) | Formulaciones oftalmicas de fluticasona y metodos de uso. | |
| DK1776349T3 (da) | 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE) | |
| EA201990752A1 (ru) | Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы | |
| CL2007002386A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. | |
| CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| BRPI0518247A2 (pt) | composiÇÕes compreendo inibidores de cinases jun n-terminais e uso | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| DK1692092T3 (da) | Anvendelse af bis-aminer til forstærkning af den antimikrobielle aktivitet af vandige sammensætninger | |
| HK1246206A1 (zh) | 用於治疗青光眼的组合物和方法 | |
| EA200700772A1 (ru) | Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний | |
| DE60135972D1 (de) | Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension |